Hoth Therapeutics Partners Altasciences For Manufacturing HT-TBI For Traumatic Brain Injury/Stroke
(RTTNews) - Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Tuesday that it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation.
HT-TBI is being developed as a novel, point-of-care therapy for the treatment and/or prevention of secondary brain injury resulting from ischemic stroke and traumatic brain injury (TBI).
HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel.
The HT-TBI formulation development and manufacturing work by Altasciences will be used to support a future Investigational New Drug (IND) Application to initiate clinical trials.
For More Such Health News, visit rttnews.com
Hoth Therapeutics Partners Altasciences For Study On HT-KIT Cancer Treatment
Hoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDA
Hoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer Disorders
U.S. Dollar Falls Against Euro, Pound
Swiss Market Ends On Weak Note
European Markets Close Weak On Growth Concerns, Fading Fed Rate Cut Hopes
Canadian Market Rebounds From Early Setback; Technology, Energy Stocks Rise
